28,700 people with type 1 diabetes in Kuwait
Dr. Walid Al-Dahhi, Chairman of the Kuwait Diabetes Association, affirmed that the smart insulin pump “Omnipod 5” represents one of the latest advanced technologies used in the treatment of type 1 diabetes patients in Kuwait. He noted that rapid advancements in medical technology have brought about a significant shift in insulin delivery methods and blood glucose control, helping patients manage their condition more effectively.
This statement was made on the sidelines of a specialized scientific event held under the patronage and participation of the Kuwait Diabetes Association. The event showcased the latest developments in the treatment of type 1 diabetes using modern devices and technologies, most notably the smart insulin pump “Omnipod 5,” and included discussions on patient needs and the rapid advancements in insulin pumps.
Al-Dahhi stated that smart pumps have become an advanced means of providing patients with a more flexible and precise method of insulin delivery, contributing to improved blood glucose control and a reduction in episodes of hypoglycemia and hyperglycemia. He explained that “Omnipod 5” relies on a technology that links blood glucose readings with the insulin delivery system, where the readings are processed through algorithms within the system to adjust insulin doses according to the patient’s needs.
He added that this technology provides a high level of automated diabetes management, noting that medical technology in the field of diabetes treatment is advancing rapidly. He highlighted that new generations of insulin pumps have become smarter, smaller, and easier to use, offering type 1 diabetes patients more advanced and flexible treatment options.
Al-Dahhi clarified that some modern adhesive pump systems are changed every three days, significantly reducing the burden of repeated injections. He pointed out that a type 1 diabetes patient may require four or five insulin injections daily under traditional regimens.
He emphasized that reducing the frequency of needle insertions makes a significant difference for patients, especially children and young individuals who require continuous insulin. He affirmed that the goal of modern technology is not limited to facilitating treatment administration but extends to improving the patient’s quality of life.
He noted that the global market is witnessing significant competition and development in the field of insulin pumps. These technologies hold particular importance in Kuwait, given available data indicating that the number of people living with type 1 diabetes in the country is estimated at approximately 28,739. This reflects the need to continue developing therapeutic services and leveraging modern technologies in disease management. He confirmed that Kuwait is among the leading countries in the Gulf and the Arab region in providing insulin pumps to type 1 diabetes patients, driven by a commitment to offering the latest treatment methods and medical technologies, particularly for children and adolescents.
Al-Dahhi underscored the importance of specialized scientific events in informing physicians and specialists about the latest developments in the treatment of type 1 diabetes. He explained that the event included several scientific lectures discussing patient needs, advancements in insulin pumps, and the latest technologies used in this field.
He stressed that keeping pace with these developments aims to provide more advanced treatment options for type 1 diabetes patients in Kuwait.
